ID3 Prescribing Patterns for Treatment of Upper Respiratory Infections

OBJECTIVE: This purpose of this study was to estimate the value of HIV prevention using the contingent valuation methodology.
METHODS: Two convenience samples of 452 high-risk individuals (homosexual) and 155 low-risk individuals (heterosexual) were collected from selected sites across the state of Missouri. Subjects completed a 60 item questionnaire on their knowledge, attitudes, beliefs, and sexual behaviors. A series of willingness to pay (WTP) questions were asked to estimate the value of 98% protection (i.e., condom use) and 100% protection (i.e., abstinence) from HIV infection. Additionally, two willingness to be paid (WTBP) questions were asked to estimate the cost of behavior change.
RESULTS: The results of the study showed high-risk individuals placed a greater value on the benefits of HIV prevention than did individuals at low-risk of HIV infection. The benefits of condom use against infection from HIV were valued at $261/month for subjects in the high-risk sample and $238/month for individuals in the low-risk sample. The average monetary benefits of abstinence against HIV infection were estimated at $305/month for high-risk individuals, compared to $249/month among individuals in the low-risk sample. Utility for each preventive behavior (condom use and abstinence) was calculated using a cost-to-benefit ratio (WTBP/WTP). Utilities were regressed on demographic and risk variables. a high-risk individual's utility for 98% protection was associated with greater exposure risk to HIV and knowledge of an AIDS-related death. The low-risk sample was not statistically significant, and no statistical relationships were found between independent variables.
CONCLUSIONS: While subject to methodological limitations, the results from this research provide estimates of the value of HIV prevention strategies. Further research in the area of WTP and HIV prevention is advocated.     

Male Andropause : A Myth or Reality

Male andropause, male climacteric or viropause is a condition in which men suffer from complex symptomatology due to low androgen level with aging. After the age of 40 years testosterone level starts declining and andropause corresponds to the age at which a pathogenic threshold is reached. This review summarizes the etiology, consequences, screening, diagnosis, monitoring of androgen deficiency in aging male (ADAM). The pros and cons of testosterone replacement therapy (TRT) in elderly male have been discussed. Currently oral, transdermal, transbuccal, intramuscular, and subcutaneous implants are available for clinical use. The choice is made by physicians based on therapeutic indication and patient preferences.Key Words: Andropause, Aging male, Testosterone replacement therapy     

Pseudo-Bernard-Soulier syndrome: thrombocytopenia caused by autoantibody to platelet glycoprotein Ib

The Bernard-Soulier syndrome is an inherited bleeding disorder that is due to a deficiency in platelet glycoprotein Ib. Bernard-Soulier platelets fail to agglutinate in response to ristocetin despite normal levels of factor VIII:von Willebrand factor. We report a patient who developed severe refractory thrombocytopenia postsurgically while receiving procainamide therapy. Thrombocytopenia was immune mediated since the patient's platelets bore high levels of antiplatelet antibody. Radioimmunoprecipitation studies demonstrated that the autoantibodies had specificity for platelet glycoproteins Ib and V as well as platelet HLA. The patient's plasma as well as purified immunoglobulin G completely inhibited the ristocetin-induced aggregation of normal platelets but did not inhibit adenosine diphosphate-induced aggregation. The laboratory studies revealed that this patient suffered from antibody-mediated thrombocytopenia with unusual characteristics that we have called pseudo-Bernard-Soulier syndrome.     

Steady‐state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir‐boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers

Objective

An open‐label, three‐period pharmacokinetic study was conducted to investigate the drug interaction potential between fosamprenavir (FPV) and tenofovir disoproxil fumarate (TDF).

Methods

Thirty‐six healthy subjects received TDF 300 mg once daily (qd) for 7 days (period 1), and then were randomized to 14 days of either FPV 1400 mg twice daily (bid) or FPV/ritonavir (RTV) 700/100 mg bid alone or with TDF (period 2). Subjects continued their randomized dose of FPV for 14 more days, adding or removing TDF based upon its receipt in period 2 (period 3). Twenty‐four‐hour pharmacokinetic sampling was carried out on day 7 of period 1 and on day 14 of periods 2 and 3. Steady‐state plasma amprenavir (APV) and tenofovir (TFV) pharmacokinetics were assessed by noncompartmental analysis and parameter values observed with each regimen were compared using geometric mean ratios with 90% confidence intervals.

Results

After TDF coadministration, APV geometric mean minimum concentration (C_min), maximum concentration (C_max), and area under the plasma concentration–time curve (AUC) increased by 31, 3 and 7% above values observed with unboosted FPV alone; they also increased by 31, 4 and 16% above values observed with FPV/RTV alone. TFV C_min, C_max and AUC decreased by 12, 25 and 15% after FPV coadministration and by 9, 18 and 7% after FPV/RTV coadministration. No significant changes in RTV pharmacokinetics were observed. No differences were noted in adverse events among dosing periods.

Conclusions

In this evaluation of the interaction between FPV and TDF, increases in APV exposures and modest decreases in TFV exposures were observed. These were unlikely to be clinically significant.